ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors

Inclusion Criteria

• •1. Histological confirmation of locally advanced or metastatic solid tumor.
• •* That is either refractory after standard of care therapy for the disease for which standard of care therapy is not reliably effective or does not exists, or
• •* For which carboplatin has been determined to be an appropriate therapy, per the investigator, or
• •* For which docetaxel has been determined to be an appropriate therapy, per the investigator.
• •2. Eastern Cooperative Oncology Group Status of 0-2
• •3. Serum creatinine value of ≤ 1.5 times the upper limit of normal (ULN) and either an estimated creatinine clearance value as determined by the Cockcroft-Gault formula or based on a 24 hour urine collection creatinine clearance value of ≥ 50 mL/min
• •4. Adequate liver function as demonstrated by serum bilirubin \< 2 x ULN and AST and ALT ≤ 2.5 x ULN
• •5. Adequate bone marrow as demonstrated by absolute neutrophil count (ANC) ≥ 1,500/mm2 (1.5 x 109/L); Platelets ≥ 100,000/mm2 (100 x 109/L); Hemoglobin ≥ 9.0 g/dL (1.4 mmol/L)
• •6. QTc interval \< 500 msec
• •7. Left Ventricular Ejection Fraction \> 50%
• •8. Women of child-bearing potential and men must agree to use adequate contraception (one of the following listed below) prior to the study entry, for the duration of study participation and up to 3 months following completion of therapy.
• •9. Capable of understanding and complying with parameters as outlined in the protocol and able to sign informed consent, approved by an Institutional Review Board (IRB) prior to the initiation of any screening or study-specific procedures.